Clase Neera has reported a significant change in its ownership status regarding Tarsus Pharmaceuticals, Inc., as detailed in its recent SEC filing.

This filing, dated November 5, 2026, reveals that Clase Neera holds direct ownership of 14,800 shares of common stock in Tarsus Pharmaceuticals, a company recognized in the biological products sector.

Background

Clase Neera is identified under the Central Index Key (CIK) number 0002162845. The company is categorized as an "other" entity type and has no publicly listed tickers or exchanges associated with it. Its recent filings include a Form 4 also dated November 5, 2026.

What the Filing Says

The SEC filing indicates that Clase Neera has no securities owned prior to this transaction. The filing states, "shares owned following transaction: 14,800," confirming the direct ownership of these shares in Tarsus Pharmaceuticals.

Impact

This change may affect various stakeholders, including investors and market analysts observing the biological products sector. Tarsus Pharmaceuticals, identified by CIK number 0001819790, operates under the SIC classification of Biological Products (No Diagnostic Substances) [2836]. This sector is characterized by its focus on innovative therapies and products.

What's Next

The filing does not say what happens next.

Source: SEC Accession Number 0002162845-26-000004

Ownership Details

In addition to the 14,800 shares of common stock, the filing reveals that Clase Neera holds several stock options and restricted stock units (RSUs) in Tarsus Pharmaceuticals. Specifically, Clase Neera has stock options to purchase a total of 23,000 shares at an exercise price of $25.56, with an expiration date of September 6, 2031. Furthermore, there are additional stock options with varying exercise prices and expiration dates, including options priced at $19.59, $15, $35.50, $44.54, and $74.90, with expiration dates ranging from March 5, 2026, to March 6, 2036.

Moreover, Clase Neera also holds RSUs that will vest over the coming years, with a total of 2,864 shares vesting on March 15, 2027, and additional RSUs vesting in equal installments in subsequent years. This diverse portfolio of stock options and RSUs indicates a significant commitment to Tarsus Pharmaceuticals, aligning the interests of Clase Neera with the company's long-term performance.

Reporting Owner's Role

The filing identifies the reporting owner, Clase Neera, as an officer of Tarsus Pharmaceuticals, specifically holding the title of Chief Commercial Officer. This role may provide Clase Neera with insights and influence over the company's strategic direction, potentially impacting future ownership decisions and transactions.

Geographic and Contact Information

Clase Neera's mailing address is listed as 17700 Laguna Canyon Road, Floor 4, Irvine, CA 92618. This location is also associated with Tarsus Pharmaceuticals, indicating a close operational relationship between the two entities.

Source: SEC Accession Number 0002162845-26-000004